An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma.
作者信息
Shih Helen A
机构信息
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
出版信息
Neuro Oncol. 2021 Nov 2;23(11):1814-1815. doi: 10.1093/neuonc/noab179.
Abstract
摘要
相似文献
1
An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma.靶向治疗的早期尝试以及对抗成人髓母细胞瘤的鼓舞人心的新方法。
Neuro Oncol. 2021 Nov 2;23(11):1814-1815. doi: 10.1093/neuonc/noab179.
2
Targeted Therapy Makes Inroads in Medulloblastoma.靶向治疗在髓母细胞瘤治疗中取得进展。
J Natl Cancer Inst. 2015 Nov 4;107(11):djv353. doi: 10.1093/jnci/djv353. Print 2015 Nov.
3
The rationale for targeted therapies in medulloblastoma.在髓母细胞瘤中进行靶向治疗的原理。
Neuro Oncol. 2014 Jan;16(1):9-20. doi: 10.1093/neuonc/not147. Epub 2013 Dec 4.
4
Targeting mTOR as a Therapeutic Approach in Medulloblastoma.针对髓母细胞瘤的 mTOR 靶向治疗方法。
Int J Mol Sci. 2018 Jun 22;19(7):1838. doi: 10.3390/ijms19071838.
5
Medulloblastoma: need for targeted treatment.髓母细胞瘤：靶向治疗的必要性。
Expert Rev Anticancer Ther. 2006 May;6(5):649-52. doi: 10.1586/14737140.6.5.649.
6
The biologic era of childhood medulloblastoma and clues to novel therapies.儿童髓母细胞瘤的生物学时代及新疗法线索
Future Oncol. 2014 Mar;10(4):637-45. doi: 10.2217/fon.13.185.
7
Hitting the target in medulloblastoma therapy.髓母细胞瘤治疗中的靶向治疗
Drug Discov Today. 2004 Dec 1;9(23):994-5. doi: 10.1016/S1359-6446(04)03289-1.
8
Medulloblastoma--challenges in radiation therapy and the addition of chemotherapy.髓母细胞瘤——放射治疗的挑战及化疗的加入
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):261-3. doi: 10.1016/s0360-3016(99)00368-5.
9
Vincristine sulphate in the treatment of skeletal metastases from cerebellar medulloblastoma.硫酸长春新碱治疗小脑髓母细胞瘤的骨转移
J Neurosurg. 1969 Jan;30(1):42-9. doi: 10.3171/jns.1969.30.1.0042.
10
[High risk cerebellar medulloblastoma: the use of high doses of chemotherapy].[高危小脑髓母细胞瘤：高剂量化疗的应用]
An Esp Pediatr. 1997 Dec;47(6):647-50.
引用本文的文献
1
Multifocal medulloblastoma in an adult: a case report and review of the literature.成人多灶性髓母细胞瘤：一例报告并文献复习
J Cancer Res Clin Oncol. 2025 May 15;151(5):166. doi: 10.1007/s00432-025-06215-9.
2
Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience.成人髓母细胞瘤采用综合治疗的长期疗效和迟发性毒性：单中心当代经验。
Neuro Oncol. 2022 Dec 1;24(12):2180-2189. doi: 10.1093/neuonc/noac126.
本文引用的文献
1
MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.MEVITEM 研究：维莫德吉联合替莫唑胺对比替莫唑胺治疗伴有 Sonic Hedgehog 通路激活的复发性/难治性髓母细胞瘤的 I/II 期临床研究。
Neuro Oncol. 2021 Nov 2;23(11):1949-1960. doi: 10.1093/neuonc/noab087.
2
Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.聚（2-恶唑啉）纳米颗粒递药通过改善中枢神经系统药代动力学和降低全身毒性增强了 vismodegib 治疗成神经管细胞瘤的潜力。
Nanomedicine. 2021 Feb;32:102345. doi: 10.1016/j.nano.2020.102345. Epub 2020 Nov 28.
3
Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.索尼替尼和维莫德吉治疗儿科和成人 MB 患者的 I 期和 II 期临床试验：系统评价和荟萃分析。
Acta Neuropathol Commun. 2019 Jul 30;7(1):123. doi: 10.1186/s40478-019-0773-8.
4
L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma and .L-4是一种耐受性良好且口服有效的刺猬信号通路抑制剂，对髓母细胞瘤显示出强大的抗肿瘤作用。
Front Pharmacol. 2019 Feb 21;10:89. doi: 10.3389/fphar.2019.00089. eCollection 2019.
5
The whole-genome landscape of medulloblastoma subtypes.髓母细胞瘤亚型的全基因组图谱。
Nature. 2017 Jul 19;547(7663):311-317. doi: 10.1038/nature22973.
6
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.维莫德吉对复发性音猬因子亚组髓母细胞瘤具有靶向疗效：来自儿科脑肿瘤协作组II期研究PBTC-025B和PBTC-032的结果
J Clin Oncol. 2015 Aug 20;33(24):2646-54. doi: 10.1200/JCO.2014.60.1591. Epub 2015 Jul 13.
7
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.SHH 型髓母细胞瘤的基因组测序预测了 smoothened 抑制与基因型相关的反应。
Cancer Cell. 2014 Mar 17;25(3):393-405. doi: 10.1016/j.ccr.2014.02.004.
8
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.替莫唑胺联合伊立替康（TEMIRI）治疗复发性或难治性髓母细胞瘤的 II 期研究：ITCC 和 SIOPE 脑肿瘤研究的联合研究。
Neuro Oncol. 2013 Sep;15(9):1236-43. doi: 10.1093/neuonc/not097. Epub 2013 Jul 14.
9
Vismodegib.维莫德吉。
Clin Cancer Res. 2012 Jun 15;18(12):3218-22. doi: 10.1158/1078-0432.CCR-12-0568. Epub 2012 Jun 7.
10
Molecular subgroups of medulloblastoma: the current consensus.髓母细胞瘤的分子亚型：当前共识。
Acta Neuropathol. 2012 Apr;123(4):465-72. doi: 10.1007/s00401-011-0922-z. Epub 2011 Dec 2.
Zotero 插件